Illumina, Inc. $ILMN Position Reduced by Bank of New York Mellon Corp

Bank of New York Mellon Corp trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 28.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,681,046 shares of the life sciences company’s stock after selling 655,019 shares during the quarter. Bank of New York Mellon Corp owned approximately 1.09% of Illumina worth $159,649,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Parkside Financial Bank & Trust raised its stake in Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares during the period. Quent Capital LLC purchased a new position in shares of Illumina during the third quarter valued at $29,000. Cullen Frost Bankers Inc. acquired a new position in Illumina during the second quarter valued at $41,000. NewSquare Capital LLC raised its position in Illumina by 604.9% during the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after buying an additional 369 shares during the period. Finally, Mather Group LLC. purchased a new stake in Illumina in the 3rd quarter worth about $46,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $144.81 on Friday. The stock has a market capitalization of $22.13 billion, a P/E ratio of 32.47, a P/E/G ratio of 2.48 and a beta of 1.41. The business has a 50-day moving average of $138.08 and a two-hundred day moving average of $114.91. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the business earned $1.14 EPS. The firm’s revenue was up .4% compared to the same quarter last year. On average, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ILMN. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Guggenheim increased their target price on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday. Barclays boosted their price target on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a report on Monday, December 15th. Finally, Robert W. Baird set a $109.00 price target on shares of Illumina in a research note on Friday, October 31st. Six investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $127.18.

Insider Buying and Selling at Illumina

In other Illumina news, Director Scott Gottlieb bought 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the purchase, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.60% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.